23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Focus

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Focus.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Try Life Science Focus now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Lilly’s triple-G drug outperforms Ozempic in head-to-head trial

Danish drug candidate shows great response to two cancer types

Cell therapy scrapped after patient deaths in trial — 94 per cent of staff laid off
Advertisement
Medtech

Abbott sharpens cancer test – detects smaller traces of tumour DNA
Sponsored content News from our members
GRUBER A/S

GRUBER aims to eliminate bottlenecks in pharmaceutical production
Aurevia

What if some of the most influential systems in healthcare are the least regulated?
Aurevia

From regulatory requirements to clinical reality: putting clinical & performance evidence into focus
GRUBER A/S

Let's connect at COMPAMED 2026 in Düsseldorf
OEM Automatic AB

Effektiv flödesmätning för vatten- och avloppssystem med FLUXUS WD
See all announcements

Danish heart drug developer heads for Swedish stock market
Advertisement
People & Careers

AlzeCure CEO steps down – co-founder takes over
Advertisement

Xbrane wins long-awaited FDA approval for eye drug biosimilar

New lung cancer combo shown to extend survival by eight months
Advertisement
Interview

Early gene therapy offers hope for some ALS patients
Advertisement
Advertisement

J&J hails early prostate cancer data as “the best we have ever seen”
Advertisement

Roche scores phase III win with lung cancer drug
People & Careers

Vitrolife appoints Elin Frostehav as new CEO
Advertisement

AstraZeneca’s ADC candidate beats expectations – new phase III data at ESMO
Advertisement

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.047|